These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26369826)

  • 1. Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors.
    Sabbah DA; Hu J; Zhong HA
    Curr Top Med Chem; 2016; 16(13):1413-26. PubMed ID: 26369826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
    Ameriks MK; Venable JD
    Curr Top Med Chem; 2009; 9(8):738-53. PubMed ID: 19689378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
    Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
    J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of highly potent and selective PI3Kδ inhibitors.
    Marcoux D; Qin LY; Ruan Z; Shi Q; Ruan Q; Weigelt C; Qiu H; Schieven G; Hynes J; Bhide R; Poss M; Tino J
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2849-2853. PubMed ID: 28209465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in development of phosphatidylinositol 3-kinase inhibitors.
    Kong D; Yamori T
    Curr Med Chem; 2009; 16(22):2839-54. PubMed ID: 19689267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
    Barlaam B; Cosulich S; Fitzek M; Germain H; Green S; Hanson LL; Harris CS; Hancox U; Hudson K; Lambert-van der Brempt C; Lamorlette M; Magnien F; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
    Bioorg Med Chem Lett; 2017 Jul; 27(13):3030-3035. PubMed ID: 28526367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
    Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
    Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of class I, II and III PI 3-kinases in platelet production and activation and their implication in thrombosis.
    Valet C; Severin S; Chicanne G; Laurent PA; Gaits-Iacovoni F; Gratacap MP; Payrastre B
    Adv Biol Regul; 2016 May; 61():33-41. PubMed ID: 26714793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
    Wu P; Hu YZ
    Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
    Miller MS; Maheshwari S; McRobb FM; Kinzler KW; Amzel LM; Vogelstein B; Gabelli SB
    Bioorg Med Chem; 2017 Feb; 25(4):1481-1486. PubMed ID: 28129991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3 kinase inhibitors in the clinic: an update.
    Kurtz JE; Ray-Coquard I
    Anticancer Res; 2012 Jul; 32(7):2463-70. PubMed ID: 22753702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
    Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
    Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of small-molecule inhibitors that target PI3Kβ.
    Yu Y; Gu D; Cai L; Yang H; Sheng R
    Drug Discov Today; 2024 Jan; 29(1):103854. PubMed ID: 38070704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
    Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
    Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors.
    Ma CC; Liu ZP
    Anticancer Agents Med Chem; 2017; 17(3):395-403. PubMed ID: 26902599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine derivatives as selective inhibitors of PI3Kα.
    Yin Y; Zhang YQ; Jin B; Sha S; Wu X; Sangani CB; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
    Bioorg Med Chem; 2015 Mar; 23(6):1231-40. PubMed ID: 25693787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
    Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
    Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitors.
    Bhide RS; Neels J; Qin LY; Ruan Z; Stachura S; Weigelt C; Sack JS; Stefanski K; Gu X; Xie JH; Goldstine CB; Skala S; Pedicord DL; Ruepp S; Dhar TG; Carter PH; Salter-Cid LM; Poss MA; Davies P
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4256-60. PubMed ID: 27476421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting phosphoinositide 3-kinase: moving towards therapy.
    Marone R; Cmiljanovic V; Giese B; Wymann MP
    Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.